Latest Insider Transactions at Adaptive Biotechnologies Corp (ADPT)
This section provides a real-time view of insider transactions for Adaptive Biotechnologies Corp (ADPT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Adaptive Biotechnologies Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Adaptive Biotechnologies Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 15
2024
|
Kyle Piskel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,260
+16.82%
|
-
|
|
Mar 12
2024
|
Peter M Neupert Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+8.14%
|
$0
$0.84 P/Share
|
|
Mar 05
2024
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
48,673
-0.93%
|
$146,019
$3.44 P/Share
|
|
Mar 05
2024
|
Tycho Peterson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,456
-2.83%
|
$46,368
$3.44 P/Share
|
|
Mar 05
2024
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
39,070
-3.89%
|
$117,210
$3.5 P/Share
|
|
Mar 05
2024
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
SELL
Open market or private sale
|
Direct |
29,390
-4.2%
|
$88,170
$3.44 P/Share
|
|
Mar 05
2024
|
Francis Lo Chief People Officer |
SELL
Open market or private sale
|
Direct |
14,700
-2.76%
|
$44,100
$3.44 P/Share
|
|
Mar 05
2024
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
13,381
-3.8%
|
$40,143
$3.44 P/Share
|
|
Mar 05
2024
|
Kyle Piskel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,727
-5.9%
|
$23,181
$3.43 P/Share
|
|
Mar 05
2024
|
Susan Bobulsky Chief Commercial Officer, MRD |
SELL
Open market or private sale
|
Direct |
12,991
-2.52%
|
$38,973
$3.44 P/Share
|
|
Mar 04
2024
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,328
+22.6%
|
-
|
|
Mar 04
2024
|
Peter M Neupert Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,328
+16.88%
|
-
|
|
Mar 04
2024
|
Katey Einterz Owen Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,328
+35.37%
|
-
|
|
Mar 04
2024
|
Michael J Pellini Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,328
+36.59%
|
-
|
|
Mar 04
2024
|
Chad M Robins CEO and Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
354,610
+11.9%
|
-
|
|
Mar 04
2024
|
Tycho Peterson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
147,790
+21.27%
|
-
|
|
Mar 04
2024
|
Harlan S Robins Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
354,610
+25.78%
|
-
|
|
Mar 04
2024
|
Julie Rubinstein President |
BUY
Grant, award, or other acquisition
|
Direct |
175,000
+25.48%
|
-
|
|
Mar 04
2024
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Grant, award, or other acquisition
|
Direct |
132,979
+27.15%
|
-
|
|
Mar 04
2024
|
Francis Lo Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
99,976
+27.14%
|
-
|
|
Mar 04
2024
|
Stacy L Taylor SVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
39,990
+18.21%
|
-
|
|
Mar 04
2024
|
Kyle Piskel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,740
+25.03%
|
-
|
|
Mar 04
2024
|
Michelle Renee Griffin Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,328
+37.62%
|
-
|
|
Mar 04
2024
|
Susan Bobulsky Chief Commercial Officer, MRD |
BUY
Grant, award, or other acquisition
|
Direct |
132,979
+33.73%
|
-
|
|
Dec 13
2023
|
Peter M Neupert Director |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+44.85%
|
$0
$0.84 P/Share
|
|
Nov 16
2023
|
Kyle Piskel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
259
-0.3%
|
$1,036
$4.13 P/Share
|
|
Aug 08
2023
|
Nitin Sood Chief Commercial Officer, MRD |
SELL
Open market or private sale
|
Direct |
10,550
-4.68%
|
$63,300
$6.54 P/Share
|
|
Aug 07
2023
|
Nitin Sood Chief Commercial Officer, MRD |
SELL
Open market or private sale
|
Direct |
5,652
-2.45%
|
$33,912
$6.78 P/Share
|
|
Jun 20
2023
|
Tycho Peterson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
134,961
-13.55%
|
$1,079,688
$8.14 P/Share
|
|
Jun 20
2023
|
Tycho Peterson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
134,961
+20.17%
|
$944,727
$7.3 P/Share
|
|
Jun 15
2023
|
Tycho Peterson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
70,000
-7.85%
|
$560,000
$8.53 P/Share
|
|
Jun 15
2023
|
Tycho Peterson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,328
+3.35%
|
$100,296
$7.3 P/Share
|
|
Jun 02
2023
|
Tycho Peterson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
38,000
-7.71%
|
$266,000
$7.16 P/Share
|
|
Apr 11
2023
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,308
-1.3%
|
$18,464
$8.63 P/Share
|
|
Apr 10
2023
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
817
-0.46%
|
$6,536
$8.5 P/Share
|
|
Mar 27
2023
|
Michelle Renee Griffin Director |
SELL
Open market or private sale
|
Direct |
2,341
-10.19%
|
$18,728
$8.49 P/Share
|
|
Mar 07
2023
|
Nitin Sood Chief Commercial Officer, MRD |
SELL
Open market or private sale
|
Direct |
9,813
-4.07%
|
$78,504
$8.6 P/Share
|
|
Mar 07
2023
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
17,155
-8.77%
|
$137,240
$8.6 P/Share
|
|
Mar 07
2023
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
13,387
-8.75%
|
$107,096
$8.6 P/Share
|
|
Mar 06
2023
|
Kyle Piskel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,529
-1.94%
|
$28,232
$8.58 P/Share
|
|
Mar 06
2023
|
Kyle Piskel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,735
+32.44%
|
-
|
|
Mar 06
2023
|
Leslie Trigg Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,775
+36.32%
|
-
|
|
Mar 06
2023
|
Kevin T Conroy Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,775
+39.15%
|
-
|
|
Mar 06
2023
|
Michelle Renee Griffin Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,775
+39.15%
|
-
|
|
Mar 06
2023
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,775
+16.28%
|
-
|
|
Mar 06
2023
|
Peter M Neupert Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,775
+39.15%
|
-
|
|
Mar 06
2023
|
Katey Einterz Owen Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,775
+36.32%
|
-
|
|
Mar 06
2023
|
Michael J Pellini Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,775
+39.15%
|
-
|
|
Mar 06
2023
|
Chad M Robins CEO and Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
354,610
+13.51%
|
-
|
|
Mar 06
2023
|
Harlan S Robins Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
354,610
+34.73%
|
-
|